ABOUT LUMINONC

Science with purpose. People at the center.

Where Scientific Discovery Meets Patient Empowerment.

LuminOnc is an emerging oncology technology and social-impact company bringing scientific innovation, accessible cancer research, patient empowerment, and evidence-based whole-person wellness together.

From cancer prevention through the cancer journey and survivorship, our focus is on supporting patients, caregivers, and families with knowledge, compassion, and possibility.

Flowing cobalt, cyan, and lavender light

Our Mission

To bring light to and illuminate every stage of the cancer journey for everyone involved. We aim to make cancer research and evidence-based whole-person wellness knowledge more accessible, understandable, and empowering for individuals and families across the cancer journey.

Our Vision

A future where scientific discovery, innovative technology, integrative wellness, and compassionate support work together to transform how people understand, navigate, and experience cancer—from prevention and early detection through treatment, survivorship, and beyond.

Our Approach

Evidence-based integrative approaches complement rather than replace conventional cancer care. We believe informed choices and whole-person well-being belong alongside care guided by qualified healthcare professionals.

01

Scientific Discovery & Innovation

Connecting emerging oncology science and thoughtful technology to make complex research more accessible.

02

Patient & Caregiver Empowerment

Helping individuals and families build understanding and participate in informed conversations about care.

03

Integrative & Whole-Person Wellness

Recognizing physical, emotional, mental, and social well-being throughout prevention, treatment, and survivorship.

04

Community & Social Impact

Working toward a more compassionate, connected future through accessible knowledge and meaningful collaboration.

Fatima Alisha Sohani, founder of LuminOnc

Meet the Founder

Fatima Alisha Sohani, PhD(c)

Fatima Alisha Sohani is the founder of LuminOnc, an emerging oncology technology and social-impact company dedicated to advancing scientific discovery, patient empowerment, and whole-person wellness.

A functional medicine educator with a background in oncology and a nursing education from Emory University, Fatima brings clinical experience and a passion for innovation to her work. She has completed additional training in cancer survivorship through Stanford Online and is currently pursuing doctoral studies in functional medicine.

Her vision for LuminOnc extends beyond traditional approaches to cancer education and support. She believes that scientific advancements should be accessible and understandable, that patients and families deserve to feel informed and empowered, and that evidence-based integrative wellness has an important place alongside conventional oncology care.

Through LuminOnc, Fatima aims to bridge scientific innovation and compassionate, whole-person support—helping shape a future where cancer prevention, research, treatment education, and survivorship are approached with greater knowledge, connection, and possibility.

Looking Ahead

LuminOnc is developing LuminOnc AI, an oncology research intelligence platform, as its first technology initiative. The platform is in development and is not yet an operational research service.

Looking forward, LuminOnc aspires to expand into education, evidence-based wellness knowledge, resources, support, community engagement, and partnerships. These are future ambitions, guided by scientific integrity, compassion, accessibility, empowerment, whole-person well-being, and purposeful social impact.

LuminOnc — Illuminating Every Stage.

Illuminating Every Stage.

LuminOnc brings scientific innovation, accessible knowledge, and whole-person wellness together.

Educational information only. Not medical advice. Integrative and complementary approaches support—not replace—conventional oncology care. Discuss health decisions with your qualified healthcare team.

© 2026 LuminOnc. All rights reserved.